

Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT03721588

Recruitment Status : Completed

First Posted : October 26, 2018

Last Update Posted : October 26, 2018

Sponsor:

Bozyaka Training and Research Hospital

Information provided by (Responsible Party):

Esin Erdoğan, Bozyaka Training and Research Hospital

• Study Details

- [Tabular View](#)
- [No Results Posted](#)

- [Disclaimer](#)
- [How to Read a Study Record](#)

Study Description

Go to ▼

Brief Summary:

In the presence of attention deficit hyperactivity disorder (ADHD) together with additional psychiatric diseases, the treatment process and prognosis of both ADHD and psychiatric comorbidity are adversely affected. The aim of this study is to compare the characteristics concerning the suicidal behavior of the patients with major depressive disorder (MDD) who have (ADHD+) or do not have (ADHD-) adult ADHD comorbidity and their responses to depression treatment. 96 inpatients were included in the study. Socio-demographic data form, Hamilton Depression Scale (HDRS), Wender Utah Rating Scale (WURS), Adult ADD/ADHD DSM IV- Based Diagnostic Screening and Rating Scale (A-ADHD), Personal and Social Performance Scale (PSP) were applied to the cases. In our study, depression starts at an early age in individuals with comorbid ADHD and the depression treatment progress changes negatively. This group of patients is at greater risk in terms of suicidal behavior. For these reasons, clinicians should be careful during ADHD and depression management in adults.

Condition or disease

Depressive Disorder, MajorAdult Attention Deficit Hyperactivity DisorderSuicide

[+ Show Detailed Description](#)

Study Design

Go to ▼

Study Type : Observational

Actual Enrollment : 96 participants

Observational Model: Case-Only

Time Perspective: Cross-Sectional

Official Title: Evaluation of Clinical and Suicidal Behavior Characteristics Among Urban, Turkish Middle-Age Depressive Patients With Comorbid Adult Attention Deficit Hyperactivity Disorder

Actual Study Start Date : September 1, 2015

Actual Primary Completion Date : June 1, 2017

Actual Study Completion Date : September 1, 2017

Resource links provided by the National Library of Medicine

[Genetics Home Reference](#) related topics: [Depression](#)

[MedlinePlus](#) related topics: [Attention Deficit Hyperactivity Disorder](#)

[U.S. FDA Resources](#)

Groups and Cohorts

Go to ▼

| Group/Cohort | Intervention/treatment |
|---|---|
| Major depressive disorder MDD; patients with diagnosis of major depressive disorder, Clinical interviews, psychometric scales were applied. | Other: Clinical interviews, psychometric scales were applied. |
| MDD and ADHD MDD; major depressive disorder ADHD; attention deficit hyperactivity disorder, Clinical interviews, psychometric scales were applied. | Other: Clinical interviews, psychometric scales were applied. |

Outcome Measures

Go to ▼

Primary Outcome Measures :

1. depressive inpatients with comorbid ADHD (n=48) and without comorbid ADHD (n=48) were compared according to the suicidal behavior, the onset age of depression, the response to the treatment, and psychosocial functioning. [Time Frame: 2 years]

Clinical interviews, psychometric scales were applied. 96 inpatients were included in the study. In our study, depression starts at an early age in individuals with comorbid ADHD and the depression treatment progress changes negatively. This group of patients is at greater risk in terms of suicidal behavior.

Eligibility Criteria

Go to ▼

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies](#).

Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study: All
Sampling Method: Probability Sample

Study Population

inpatients with diagnosis of major depressive disorder

Criteria

Inclusion Criteria:

Complying with DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth) criteria and Hamilton Depression Scale (HDRS) being over 16 points during hospitalization

Exclusion Criteria:

mental retardation, psychotic disorder, alcohol or substance addiction, history of significant head trauma and being under psychostimulant treatment

Contacts and Locations

Go to ▼

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its *ClinicalTrials.gov* identifier (NCT number): **NCT03721588**

Sponsors and Collaborators

Bozyaka Training and Research Hospital

Investigators

Principal Investigator: Esin Erdogan, MD Bozyaka Training and Research Hospital

More Information

Go to ▼

Publications of Results:

Duran Ş, Fıstıkçı N, Keyvan A, Bilici M, Çalışkan M. [ADHD in adult psychiatric outpatients: prevalence and comorbidity]. Turk Psikiyatri Derg. 2014 Summer;25(2):84-93. Turkish.

Agosti V, Chen Y, Levin FR. Does Attention Deficit Hyperactivity Disorder increase the risk of suicide attempts? J Affect Disord. 2011 Oct;133(3):595-9. doi: 10.1016/j.jad.2011.05.008. Epub 2011 Jun 11.

Tamam L, Demirkol ME. Adult attention deficit/hyperactivity disorder and mood disorders. *Turkiye Klin J Psychiatry-Special Top* 2012;5:48-3.

Ekinçi S, Öncü B, Canat S. Adult attention deficit hyperactivity disorder: comorbidity and functioning. *Anadolu Psikiyatr Derg* 2011;12:185-1.

Responsible Party: Esin Erdoğan, Psychiatry Department, MD, Bozyaka Training and Research Hospital

ClinicalTrials.gov Identifier: [NCT03721588](#) [History of Changes](#)

Other Study ID Numbers: dresinerdogan

First Posted: October 26, 2018 [Key Record Dates](#)

Last Update Posted: October 26, 2018

Last Verified: October 2018

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No

Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Disease

Depressive Disorder

Depression

Attention Deficit Disorder with Hyperactivity

Hyperkinesia

Suicide

Depressive Disorder, Major

Pathologic Processes

Mood Disorders

Mental Disorders

Behavioral Symptoms

Attention Deficit and Disruptive Behavior Disorders

Neurodevelopmental Disorders

Dyskinesias

Neurologic Manifestations

Nervous System Diseases

Signs and Symptoms

Self-Injurious Behavior